Fate Therapeutics, Inc. provided earnings guidance for the year 2023. For each of the remaining three quarters of 2023, the Company expects to recognize approximately $0.8 million in revenue under the ONO collaboration in connection with its conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.08 USD | +4.62% | +0.49% | +9.09% |
May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.09% | 464M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023